Meeting
2022 ASCO Annual Meeting
Integrated germline and somatic cancer testing provides opportunity to identify cancer risk and resolve variant origins.
Authors
Kingshuk Das
Invitae, San Francisco, CA
Kingshuk Das , Amber Carter , Brandie Heald , Scott T. Michalski , Sarah M. Nielsen , Nhu Ngo , Sara Elrefai , Kelly Warsinske , Stacy Lenarcic , Heather Hampel , Robert Luke Nussbaum , Edward D. Esplin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Prevention, Risk Reduction, and Hereditary Cancer
Track
Prevention, Risk Reduction, and Genetics
Sub Track
Germline Genetic Testing
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 10589)
DOI
10.1200/JCO.2022.40.16_suppl.10589
Abstract #
10589
Poster Bd #
464
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Safety of multiplex gene testing for inherited cancer risk in a fully accrued prospective trial.
First Author: Allison W. Kurian
Poster
2023 ASCO Annual Meeting
Spectrum of germline pathogenic variants among patients with cancer in Mexico.
First Author: Jose Luis Rodriguez Olivares
Poster
2019 ASCO Annual Meeting
Tumor sequencing with germline genetic testing: Identification of patients with hereditary cancer and precision treatment eligibility.
First Author: Scott T. Michalski
Poster
2019 ASCO Annual Meeting
Prevalence and penetrance of breast cancer-associated mutations identified by multiple-gene sequencing in the Women’s Health Initiative.
First Author: Allison W. Kurian